Literature DB >> 29158271

In Vitro Activities of Ceftaroline and Comparators against Streptococcus pneumoniae Isolates from U.S. Hospitals: Results from Seven Years of the AWARE Surveillance Program (2010 to 2016).

Michael A Pfaller1,2, Rodrigo E Mendes1, Leonard R Duncan1, Robert K Flamm1, Helio S Sader3.   

Abstract

We evaluated trends in Streptococcus pneumoniae antimicrobial susceptibility in United States hospitals in the 2010 to 2016 period. A total of 8,768 clinical isolates from 47 medical centers were tested for susceptibility by broth microdilution methods. Multidrug-resistant (MDR) and extensively drug-resistant (XDR) rates decreased from 25.7% and 12.4%, respectively, in 2010 to 17.7% and 3.6%, respectively, in 2016. The susceptibilities to most comparator antimicrobial agents increased, whereas the susceptibilities to ceftaroline, levofloxacin, linezolid, and tigecycline remained stable. Ceftaroline retained potent activity against S. pneumoniae (>99.9%) with no marked variations.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  S. pneumoniae; ceftaroline; cephalosporins; respiratory infection; β-lactams

Mesh：

Substances：

Year:  2018        PMID： 29158271      PMCID： PMC5786790          DOI： 10.1128/AAC.01555-17

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  13 in total

Review 1.  Ceftaroline fosamil: a review of its use in the treatment of complicated skin and soft tissue infections and community-acquired pneumonia.

Authors:  James E Frampton
Journal:  Drugs       Date:  2013-07       Impact factor: 9.546

2.  Serotype distribution and antimicrobial susceptibility of USA Streptococcus pneumoniae isolates collected prior to and post introduction of 13-valent pneumococcal conjugate vaccine.

Authors:  Rodrigo E Mendes; Andrew J Costello; Michael R Jacobs; Donald Biek; Ian A Critchley; Ronald N Jones
Journal:  Diagn Microbiol Infect Dis       Date:  2014-05-24       Impact factor: 2.803

3.  Decreased ceftriaxone susceptibility in emerging (35B and 6C) and persisting (19A) Streptococcus pneumoniae serotypes in the United States, 2011-2012: ceftaroline remains active in vitro among β-lactam agents.

Authors:  Rodrigo E Mendes; Donald Biek; Ian A Critchley; David J Farrell; Helio S Sader; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2014-05-27       Impact factor: 5.191

4.  Characterization of MDR and XDR Streptococcus pneumoniae in Canada, 2007-13.

Authors:  Alyssa R Golden; Margot Rosenthal; Ben Fultz; Kimberly A Nichol; Heather J Adam; Matthew W Gilmour; Melanie R Baxter; Daryl J Hoban; James A Karlowsky; George G Zhanel
Journal:  J Antimicrob Chemother       Date:  2015-04-28       Impact factor: 5.790

Review 5.  Burden of community-acquired pneumonia in North American adults.

Authors:  Thomas M File; Thomas J Marrie
Journal:  Postgrad Med       Date:  2010-03       Impact factor: 3.840

6.  Genomic Epidemiology of Penicillin-Nonsusceptible Pneumococci with Nonvaccine Serotypes Causing Invasive Disease in the United States.

Authors:  Cheryl P Andam; Patrick K Mitchell; Alanna Callendrello; Qiuzhi Chang; Jukka Corander; Chrispin Chaguza; Lesley McGee; Bernard W Beall; William P Hanage
Journal:  J Clin Microbiol       Date:  2017-01-18       Impact factor: 5.948

7.  Changes in pneumococcal serotypes and antimicrobial resistance after introduction of the 13-valent conjugate vaccine in the United States.

Authors:  Sandra S Richter; Daniel J Diekema; Kristopher P Heilmann; Cassie L Dohrn; Fathollah Riahi; Gary V Doern
Journal:  Antimicrob Agents Chemother       Date:  2014-08-18       Impact factor: 5.191

Review 8.  In vitro activity of ceftaroline against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae: a review of published studies and the AWARE Surveillance Program (2008-2010).

Authors:  David J Farrell; Mariana Castanheira; Rodrigo E Mendes; Helio S Sader; Ronald N Jones
Journal:  Clin Infect Dis       Date:  2012-09       Impact factor: 9.079

9.  AWARE Ceftaroline Surveillance Program (2008-2010): trends in resistance patterns among Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States.

Authors:  Michael A Pfaller; David J Farrell; Helio S Sader; Ronald N Jones
Journal:  Clin Infect Dis       Date:  2012-09       Impact factor: 9.079

10.  Antimicrobial activity of ceftaroline tested against drug-resistant subsets of Streptococcus pneumoniae from U.S. medical centers.

Authors:  Robert K Flamm; Helio S Sader; David J Farrell; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2014-02-10       Impact factor: 5.191
View more
  9 in total

1.  Pharmacokinetic/Pharmacodynamic Evaluation of Solithromycin against Streptococcus pneumoniae Using Data from a Neutropenic Murine Lung Infection Model.

Authors:  Olanrewaju O Okusanya; Alan Forrest; Sujata M Bhavnani; Prabhavathi Fernandes; Paul G Ambrose; David R Andes
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

2.  Cost-Saving Opportunities with an Oral and Intravenous Once-Daily Aminomethylcycline Antibiotic for Hospitalized Patients with Community-Acquired Bacterial Pneumonia: Findings from Decision-Analytic Models.

Authors:  Thomas Lodise; Kenneth LaPensee
Journal:  Am Health Drug Benefits       Date:  2019 Jun-Jul

3.  Efficacy and Safety of Ceftaroline for the Treatment of Community-Acquired Pneumonia: A Systemic Review and Meta-Analysis of Randomized Controlled Trials.

Authors:  Shao-Huan Lan; Shen-Peng Chang; Chih-Cheng Lai; Li-Chin Lu; Chien-Ming Chao
Journal:  J Clin Med       Date:  2019-06-09       Impact factor: 4.241

4.  Antibiotic resistance among ocular pathogens: current trends from the ARMOR surveillance study (2009-2016).

Authors:  Randall K Thomas; Ron Melton; Penny A Asbell
Journal:  Clin Optom (Auckl)       Date:  2019-03-12

5.  Antimicrobial Susceptibility of Streptococcus pneumoniae from North America, Europe, Latin America, and the Asia-Pacific Region: Results From 20 Years of the SENTRY Antimicrobial Surveillance Program (1997-2016).

Authors:  Helio S Sader; Rodrigo E Mendes; Jennifer Le; Gerald Denys; Robert K Flamm; Ronald N Jones
Journal:  Open Forum Infect Dis       Date:  2019-03-15       Impact factor: 3.835

6.  Trends in Antibiotic Resistance Among Ocular Microorganisms in the United States From 2009 to 2018.

Authors:  Penny A Asbell; Christine M Sanfilippo; Daniel F Sahm; Heleen H DeCory
Journal:  JAMA Ophthalmol       Date:  2020-05-01       Impact factor: 7.389

7.  Serotype distribution and antimicrobial susceptibility of Streptococcus pneumoniae isolates from a Phase III community-acquired bacterial pneumonia (CABP) trial.

Authors:  S P McCurdy; A J Sheets; S K Cammarata; J E Vidal
Journal:  JAC Antimicrob Resist       Date:  2021-05-04

8.  Carbapenems drive the collateral resistance to ceftaroline in cystic fibrosis patients with MRSA.

Authors:  Maria Celeste Varela; Melanie Roch; Agustina Taglialegna; Scott W Long; Matthew Ojeda Saavedra; Warren E Rose; James J Davis; Lucas R Hoffman; Rafael E Hernandez; Roberto R Rosato; Adriana E Rosato
Journal:  Commun Biol       Date:  2020-10-22

9.  A Multicenter Evaluation of the US Prevalence and Regional Variation in Macrolide-Resistant S. pneumoniae in Ambulatory and Hospitalized Adult Patients in the United States.

Authors:  Vikas Gupta; Kalvin C Yu; Jennifer Schranz; Steven P Gelone
Journal:  Open Forum Infect Dis       Date:  2021-02-04       Impact factor: 3.835
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.